Abstract: A technique may include receiving, by a management service a plurality of instance configurations from a client device. The technique may then include receiving, by the management service, information identifying a launch request for a compute instance. The technique may include determining, by the management service, one or more candidate shapes for the compute instance based at least in part on the plurality of instance configurations. The technique may include selecting, by the management service and from the one or more candidate shapes, a launch shape for the compute instance and launching the compute instance using the launch shape. The technique may then include providing, the client device access to the compute instance, launched based on the launch shape.

Abstract: A technique may include receiving, by a management service a plurality of instance configurations from a client device. The technique may then include receiving, by the management service, information identifying a launch request for a compute instance. The technique may include determining, by the management service, one or more candidate shapes for the compute instance based at least in part on the plurality of instance configurations. The technique may include selecting, by the management service and from the one or more candidate shapes, a launch shape for the compute instance and launching the compute instance using the launch shape. The technique may then include providing, the client device access to the compute instance, launched based on the launch shape.

Abstract: A compound of the formula: is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

Abstract: The invention relates to a process for preparing quinoline-substituted carbonate and carbamate compounds, which are important intermediates in the synthesis of 6-O-substituted macrolide antibiotics. The process employs metal-catalyzed coupling reactions to provide a carbonate or carbamate of formula (I) or (II) or a substrate that can be reduced to obtain the same.

Abstract: Methods and novel intermediates for the preparation of acyclic nucleoside derivatives of the formula: where one of R1 and R2 is an amino acid acyl group and the other of R1 and R2 is a —C(O)C3-C21 saturated or monounsaturated, optionally substituted alkyl and R3 is OH or H; or a pharmaceutically acceptable salt thereof.

Abstract: Methods and novel intermediates for the preparation of acyclic nucleoside derivatives of the formula: where one of R1 and R2 is an amino acid acyl group and the other of R1 and R2 is a —C(O)C3-C21 saturated or monounsaturated, optionally substituted alkyl and R3 is OH or H; or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to processes for preparing amine substituted benzofurans, and more particularly 4-(2{2-[(2R)-2-methyl-1-pyrrolidinyl]ethyl}-1-benzofuran-5-yl)benzonitrile, and salts thereof. Compounds prepared by the processes of the invention have demonstrated activity as histamine-3 receptor ligands.

Abstract: Methods and novel intermediates for the preparation of acyclic nucleoside derivatives of the formula: 1

Abstract: Methods and novel intermediates for the preparation of acyclic nucleoside derivatives of the formula: 1

Abstract: Methods and novel intermediates for the preparation of acyclic nucleoside derivatives of the formula: where one of R1 and R2 is an amino acid acyl group and the other of R1 and R2 is a —C(O)C3-C21 saturated or monounsaturated, optionally substituted alkyl and R3 is OH or H; or a pharmaceutically acceptable salt thereof.

Abstract: Methods and novel intermediates of the formula: wherein R6 and R7 are lower alkyl or benzyl or R6 and R7 taken together are —CH2CH2—, —CH2CH2CH2— or —CH2CH2CH2CH2CH2—, R8 is C1-C21 alkyl or a C2-C21 monounsaturated alkenyl, which may optionally be substituted with substitution substituents independently selected from the group consisting of hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkoxy C1-C6 alkyl, C1-C6 alkanoyl, amino, halo, cyano, azido, oxo, mercapto and nitro, and R9 is an alcohol protecting group. The intermediates are useful for the preparation of acyclic nucleoside derivatives of the formula: where one of R1 and R2 is an amino acid acyl group and the other of R1 and R2 is a —C(O)C3-C21 saturated or monounsaturated, optionally substituted alkyl and R3 is OH or H; or a pharmaceutically acceptable salt thereof.